![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ensho has the right to develop, manufacture, and commercialize a portfolio of oral alpha-4 beta-7 integrin integrin inhibitors, EA1080 (NSHO-101), globally, excluding certain Asian jurisdictions.
Lead Product(s): NSHO-101
Therapeutic Area: Gastroenterology Product Name: EA1080
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ensho Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 27, 2024
Details:
Under the terms of the license agreement, Ensho will conduct global clinical studies for EA1080, which is being evaluated in the early-stage clinical studies for inflammatory bowel disease.
Lead Product(s): NSHO-101
Therapeutic Area: Gastroenterology Product Name: EA1080
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ensho Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 27, 2024
Details:
MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per sachet.
Lead Product(s): Macrogol
Therapeutic Area: Gastroenterology Product Name: Movicol HD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mochida Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Actonel (risedronate sodium hydrate) tablet act as inhibits osteoclasts, which is indicated for the treatment of Paget’s disease and treatment and prevention of postmenopausal osteoporosis.
Lead Product(s): Risedronate Sodium
Therapeutic Area: Rare Diseases and Disorders Product Name: Actonel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020